Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical management of metastatic castration-resistant prostate cancer patients

BACKGROUND: Enzalutamide is a potent androgen-signaling receptor inhibitor and is licensed for the treatment of metastatic castration-resistant prostate cancer. N-desmethylenzalutamide is the active metabolite of enzalutamide. A method to quantitate enzalutamide and its active metabolite was develop...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Drug Monit
Autors principals: Benoist, Guillemette E, van der Meulen, Eric, van Oort, Inge M, Beumer, Jan Hendrik, Somford, Diederik M, Schalken, Jack A, Burger, David M, van Erp, Nielka P
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6085835/
https://ncbi.nlm.nih.gov/pubmed/29419723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FTD.0000000000000484
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars